Registration Dossier

Administrative data

Link to relevant study record(s)

Description of key information

Absorption: assumed  oraly and dermaly well absorbed; inhalation negligible
Distribution: no information
Metabolism: no information
Excretion: no information

Key value for chemical safety assessment

Bioaccumulation potential:
high bioaccumulation potential

Additional information

No ADME and dermal absorption study with the Gaskamine 240 are available.

 

However, three oral toxicity studies give an indication about the bioavailability after oral application. In an acute toxicity study, one 28 days repeated dose toxicity study and one reproductive/developmental toxicity screening study systemic toxicity was observed after oral Gaskamine 240 exposure leading to the conclusion that the test substance is bioavailable after oral application.

 

After dermal application in a mice sensitization study (local lymph node assay) the substance provoke skin sensitization suggesting sufficient dermal absorption. The octanol/water partition coefficient is determined with > 6.2 (30°C) indicates high lipophilic property of the substance and the mean molecular weight is with 292.4 g/mol rather low. Therefore, a good dermal absorption rate of Gaskamine 240 can be assumed.

 

Gaskamine 240 is a viscous liquid at room temperature and vaporization is deemed negligible as the vapour pressure is 1.3 x 10-5 Pa (25 C°). Therefore, inhalation exposure is only possible via aerosols of dissolved material.

 

Gaskamine 240 is hydrolytically stable in neutral, acidic and alkaline solutions at room temperature. Therefore it can be assumed that no hydrolysis takes place during the rather fast stomach passage and the unchanged substance reaches the small intestine where it might be absorbed. No chemical hydrolysis can be expected in the blood and intracellular. Due to the low water solubility and the high partition coefficient of Gaskamine 240 accumulation in fatty tissues is likely after entering the body.